Evidence map›Paper›PMID 19245660›Full record

ArticleJournal of neurochemistry2009

The purine nucleosides adenosine and guanosine delay axonal degeneration in vitro.

Craig Press, Jeffrey Milbrandt

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of neurochemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Craig PressDepartment of Pathology, Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, Missouri, USA.
Jeffrey Milbrandt
Hope Center for Neurological Disorders · US

Funding

PHYSIOLOGY AND GENETICS OF THE GDNF HOMOLOG NEURTURINR01AG013730 · NIA · WASHINGTON UNIVERSITY · PI JEFFREY D MILBRANDT · 1996 to 2026
$10.6M
Washington University Center for Translational NeuroscienceP30NS057105 · NINDS · WASHINGTON UNIVERSITY · PI HOLTZMAN, DAVID M. · 2006 to 2011
$8.7M
ROLE OF EGR2 MUTATIONS IN PERIPHERAL MYELINOPATHIESR01NS040745 · NINDS · WASHINGTON UNIVERSITY · PI MILBRANDT, JEFFREY D · 2001 to 2009
$3.3M
NIA NIH HHS AG013730NIA NIH HHS R01 AG013730NINDS NIH HHS NS040745NINDS NIH HHS NS057105NINDS NIH HHS P30 NS057105NINDS NIH HHS R01 NS040745
6 · The paper itself

Abstract

Axonal degeneration is a key component of many neurodegenerative diseases. Injured axons undergo a program of self-destruction termed Wallerian degeneration that is an active, well-regulated process. The pathways leading to axon fragmentation are uncharacterized, but experiments with wld(s) mutant mice led to the discovery that over-expression of NMN adenylyltransferase 1 or treatment with NAD(+) can inhibit axonal degeneration. In this study, we show that the purine nucleosides adenosine and guanosine, but not inosine, inhibit injury-induced axonal degeneration in cultured dorsal root ganglia neurons. Axons can be preserved by adding adenosine within 6 h of the axonal injury. The presence of adenosine was required continuously after the injury to maintain axonal protection. Together these results suggest that adenosine does not alter the neuronal response to injury, but instead inhibits a local axonal pathway necessary for the commitment and/or execution of the axon destructive program.

Indexed as

AdenosineAnimalsAxonsCells, CulturedGanglia, SpinalGuanosineMiceNerve DegenerationPurine NucleosidesWallerian DegenerationAdenosineGuanosinePurine Nucleosides

Identifiers

PMID19245660
PMCPMC2682787
OpenAlexW2082168773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.